Chloroquine, Hydroxychloroquine, and Your Retina at a Glance
Both drugs can, rarely, damage the retina, and the damage can be lasting. Chloroquine has long been considered more toxic to the retina than hydroxychloroquine, though recent studies directly comparing the two are limited1. For most people the bigger question is not which pill it is, but the daily dose relative to body weight and how many years it is taken. The reassuring part: at recommended doses the risk in the early years is low, and regular screening is designed to catch changes before you notice them.
Chloroquine and hydroxychloroquine are close chemical cousins, both first used against malaria and now widely used for lupus and rheumatoid arthritis. Because they work in similar ways, they share the same rare but serious eye risk. If your rheumatologist has offered one over the other, it helps to understand what actually drives retinal risk, so you can weigh it sensibly rather than fearfully.
This page compares what each drug is, how they compare on retinal safety, what damage looks like and whether it reverses, and how screening protects your vision. It is general education, not a reason to change or stop a prescribed medicine on your own. Any dosing or switching decision belongs with the doctor who prescribes it and the eye doctor who screens you.
What Each Drug Is
Hydroxychloroquine is the more commonly prescribed of the two today, especially for autoimmune disease. It is used to prevent and treat malaria and to treat lupus and rheumatoid arthritis, and it may cause serious and potentially irreversible eye problems, so people usually need regular eye exams during treatment2. For most patients it is well tolerated, and the eye risk is low when the dose is kept within weight-based limits and screening is kept up.
Chloroquine is the older of the pair and is prescribed less often now for autoimmune conditions. It is used to prevent and treat malaria and to treat amebiasis, and occasionally for rheumatoid arthritis and lupus, and long-term use calls for frequent eye exams because it can cause serious vision problems3. When a doctor does choose chloroquine, the same principles apply: right dose for body weight, and steady eye monitoring.
Both medicines bind to pigment in the retina and can slowly build up in its cells over months and years. In a small number of people that buildup injures the macula, the central part of the retina you use for sharp, straight-ahead vision. This is why the risk grows with the total amount taken over time, and why the eye, not just the joints or skin, needs watching while you are on either drug.
Which Is Harder on the Retina, Side by Side
Head-to-head, chloroquine is generally regarded as the more retina-toxic of the two, which is one reason hydroxychloroquine has largely replaced it for long-term autoimmune use. But the evidence for a large modern difference is thin, and dose and duration matter more than the choice between them. The Academy notes chloroquine may be more toxic but that no recent studies confirm this, and it advises keeping hydroxychloroquine at or below 5.0 milligrams per kilogram of body weight and chloroquine at or below 2.3 milligrams per kilogram1. That lower ceiling for chloroquine reflects its greater potency per milligram.
The weight-based limit is the single most useful number in this whole comparison, because staying under it is what keeps early risk low. These are the ceilings your prescriber and eye doctor work from, not doses to set yourself.
| Drug | Advised daily limit |
|---|---|
| Hydroxychloroquine | 5.0 mg per kg of body weight or less |
| Chloroquine | 2.3 mg per kg of body weight or less |
For most people on hydroxychloroquine at the right dose, the risk in the first decade is small. At recommended doses, fewer than 1 of every 100 people develop retinopathy within 5 years and fewer than 2 of every 100 by 10 years, with the risk rising after 20 years of use1. Across all users, including many on high or long-term doses, overall prevalence estimates fall in the range of about 7 or 8 of every 1001. The takeaway: time on the drug, not a single dose, is the main driver.
What Retinal Damage Looks Like and Whether It Reverses
Early retinal toxicity is usually silent. You typically cannot feel it, and vision can seem normal while subtle changes are already visible on a scan. As it advances, some people notice trouble reading, gaps where words or parts of objects disappear, or dimmer central vision. That silent early phase is exactly why screening exists: to find changes before they reach the part of vision you would notice.
This is the reason both drugs are taken seriously. Hydroxychloroquine can cause eye problems that are serious and potentially irreversible2. Damage already done to the macula generally does not fully reverse, though stopping the drug when toxicity is caught early can prevent further loss. The goal is never to reach that point: catch it at the silent stage, and vision you still have can usually be protected.
Some people carry more risk than the averages suggest. Beyond higher dose and longer duration, risk factors include kidney disease, use of the breast-cancer drug tamoxifen, and starting therapy at an older age1. If any of these apply to you, your eye doctor may screen you sooner or more closely. Knowing your own risk factors is worth a specific conversation, because it changes how often you should be checked.
How Screening Protects Your Vision
Screening for these drugs is not a routine glasses check; it uses specific retinal imaging. Recommended screening includes a baseline eye exam near the start of therapy plus annual imaging with OCT (a retinal scan) and wide-field fundus autofluorescence, though annual screening may reasonably be deferred during the first 5 years if you have no significant risk factors1. These tests are painless and are the best way to catch silent changes early.
The plan only works if the visits happen. Ask your prescriber to confirm your baseline eye exam is booked when you start, then keep the follow-up schedule your eye doctor sets. If you change how much you take, or start a drug like tamoxifen, tell your eye doctor, since your screening interval may need to change. Missing years of screening is the main avoidable way this risk turns into vision loss.
When to Call Your Doctor
Because early damage is silent, do not wait for symptoms to decide screening matters, but do report new vision changes promptly. Tell your doctor if you have blurred vision, floaters, flashes of light, or other changes in vision while taking hydroxychloroquine2. New trouble reading, or spots where words or parts of an image seem to vanish, also deserve a prompt call. These do not always mean toxicity, but they are worth checking without delay.
Chloroquine carries a specific label warning. If you experience vision changes such as light flashes and streaks, blurred vision, or reading difficulty while taking chloroquine, stop taking it and call your doctor immediately3. This is the drug's own labeled instruction. For hydroxychloroquine, report changes promptly but do not stop a prescribed drug on your own; let the prescriber and eye doctor guide any change.
Two doctors share it: the prescriber, often a rheumatologist, who sets the drug and dose, and an eye doctor who screens your retina. Neither part works alone. If you are on either drug and have never had a baseline retinal screening, that is worth arranging now rather than at your next routine visit.
Common Questions About These Drugs and Your Eyes
For long-term autoimmune use, hydroxychloroquine is generally preferred, partly on the view that chloroquine is harder on the retina. The evidence for a large modern difference is limited, and dose relative to body weight and years of use matter more than which drug it is1. The safest version of either drug is the right weight-based dose with screening kept up. This is a decision to make with your prescriber, based on your condition and risk factors.
No. Serious vision loss is uncommon when dosing and screening are done well. At recommended doses, fewer than 2 of every 100 people develop retinopathy even after 10 years1. The risk rises with very long use, which is exactly why screening continues year after year. Caught at the silent stage, toxicity can usually be stopped before it reaches vision you would notice. The plan is designed to keep you well within that safe zone.
Yes, dose for your body weight is one of the strongest levers on risk. The Academy advises keeping hydroxychloroquine at or below 5.0 mg per kg of real body weight, at which the early risk stays low1. This is why your prescriber calculates your dose from your weight rather than giving everyone the same amount. If you are unsure whether your dose fits your weight, ask your prescriber to review it with you.
Yes, and this is the most important point on the page. Early toxicity usually causes no symptoms, so normal-feeling vision is not proof your retina is fine. People taking hydroxychloroquine will probably need regular eye exams during treatment2. The screening scans see changes long before you would. Skipping exams because you feel fine is the single most common way this preventable damage is missed.
Damage already done to the macula generally does not fully reverse. Hydroxychloroquine can cause eye problems that are serious and potentially irreversible2. What stopping the drug early can do is prevent further loss. That is the whole logic of screening: find it while it is silent and reversible harm is still avoidable, rather than after vision has changed. Prevention and early detection, not treatment after the fact, are where the wins are.
More Questions to Discuss With Your Team
Maybe, but that is a prescriber's decision, not a change to make yourself. Many patients are on hydroxychloroquine partly because it is viewed as easier on the retina, but chloroquine is sometimes the right choice for a given person. Chloroquine may be more toxic to the retina, though no recent studies confirm the size of the difference1. Bring the question to your rheumatologist, who can weigh your condition, dose, and eye-screening results together.
Ask specifically for the recommended retinal screening, not just a vision and glasses check. Screening should include a baseline exam plus annual OCT and wide-field fundus autofluorescence, with the first 5 years sometimes deferred if you have no significant risk factors1. If your eye doctor is not doing these specific scans, ask whether you should see one who screens for medication-related retinal toxicity. The right tests are what make early detection possible.
- Is my daily dose within the recommended limit for my body weight?
- Do I have any risk factors, such as kidney disease or tamoxifen use, that raise my risk?
- When is my baseline retinal screening, and how often should I be screened after that?
- Are you using OCT and fundus autofluorescence, or just a routine eye exam?
- Given my eyes, is hydroxychloroquine or chloroquine the better choice for me?
- What vision changes should make me call you right away?